Hansen Medical Announces Fourth Quarter and Full-Year 2012 Results Conference Call

Hansen Medical Announces Fourth Quarter and Full-Year 2012 Results Conference 
Call 
MOUNTAIN VIEW, CA -- (Marketwire) -- 02/13/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that it will release its financial and operating results
for the fourth quarter and full year ended December 31, 2012 after
market close on Wednesday, February 27, 2013. 
Bruce Barclay, President and Chief Executive Officer, will hold a
conference call at 5:00 p.m. ET (2:00 p.m. PT) on February 27, 2013
to discuss the company's results. The call may be accessed by dialing
877-941-1427 (480-629-9664 for international callers) and via the
Internet in the Investor Relations section of Hansen Medical's
website at www.hansenmedical.com. Please go to the website at least
15 minutes early to register, download and install any necessary
audio software. Following the call, a webcast replay will be
available on Hansen Medical's website, and an audio replay will also
be available by calling 877-870-5176 (858-384-5517 for international
callers) and entering the access code 4593337. The audio replay will
be available through March 6, 2013. 
About Hansen Medical, Inc.  
Hansen Medical, Inc., based in Mountain View, California, is the
global leader in intravascular robotics, developing products and
technology designed to enable the accurate positioning, manipulation
and control of catheters and catheter-based technologies. The
Company's Magellan(TM) Robotic System, NorthStar(TM) Robotic Catheter
and related accessories, which are intended to facilitate navigation
to anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union, and the U.S. The Company has
recently launched a limited commercial evaluation program to allow
certain strategic accounts to install and utilize its Systems for a
trial period while the purchase contract is being evaluated by the
hospital. The participating hospitals are under no obligation to make
a purchase upon the completion of the trial period. In the European
Union, the Company's Sensei(R) X Robotic Catheter System and Artisan
Control
 Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx(R) Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S. the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the U.S.
Food and Drug Administration for manipulation and control of certain
mapping catheters in EP procedures. In the United States, the Sensei
System is not approved for use in guiding ablation procedures; this
use remains experimental. The U.S. product labeling therefore
provides that the safety and effectiveness of the Sensei X System and
Artisan Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
www.hansenmedical.com.  
Forward-Looking Statements  
This press release contains forward-looking statements regarding,
among other things, statements relating to goals, plans, objectives,
milestones and future events. All statements, other than statements
of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the words
"plan," "expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date of
this press release and are subject to risks, uncertainties, changes
in circumstances and other factors that may cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Examples of
such statements include statements about the potential benefits of
our technology and the value of our intellectual property portfolio.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
include, among others: engineering, regulatory, manufacturing, sales
and customer service challenges in developing new products and
entering new markets; potential safety and regulatory issues that
could slow or suspend our sales; the effect of credit, financial and
economic conditions on capital spending by our potential customers;
the uncertain timelines for the sales cycle for newly introduced
products; the rate of adoption of our systems and the rate of use of
our catheters; the scope and validity of intellectual property rights
applicable to our products; competition from other companies; our
ability to recruit and retain key personnel; our ability to maintain
our remedial actions over previously reported material weaknesses in
internal controls over financial reporting; our ability to manage
expenses and cash flow, and obtain additional financing; and other
risks more fully described in the "Risk Factors" section of our
Quarterly Report on Form 10-Q for the quarter ended September 30,
2012 filed with the SEC on November 9, 2012 and the risks discussed
in our other reports filed with the SEC. Given these uncertainties,
you should not place undue reliance on the forward-looking statements
in this press release. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the future,
even if new information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contacts:
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.
650.404.5800 
FTI Consulting, Inc.
Brian Ritchie
212.850.5683
brian.ritchie@fticonsulting.com  
John Capodanno
212.850.5705
John.capodanno@fticonsulting.com 
 
 
Press spacebar to pause and continue. Press esc to stop.